Macquarie Group
CUE icon

Macquarie Group’s Cue Biopharma CUE Stock Holding History

Macquarie Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60
Closed -$2.24K – 1720
2024
Q2 		$2.24K Buy
+60
New +$2.97K ﹤0.01% 1795
2022
Q2 		– Sell
-200
Closed -$29 – 2582
2022
Q1 		$29 Hold
200
– – ﹤0.01% 2300
2021
Q4 		$68K Sell
200
-67
-25% -$25.9K ﹤0.01% 2062
2021
Q3 		$117K Buy
267
+246
+1,171% +$85.8K ﹤0.01% 1937
2021
Q2 		$7K Hold
21
– – ﹤0.01% 2500
2021
Q1 		$8K Sell
21
-7
-25% -$2.88K ﹤0.01% 2411
2020
Q4 		$10K Hold
28
– – ﹤0.01% 2306
2020
Q3 		$12K Hold
28
– – ﹤0.01% 2255
2020
Q2 		$20K Buy
+28
New +$20.3K ﹤0.01% 2162

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Macquarie Group's CUE Position: Q3 2024 in Review

Macquarie Group sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 60 shares — an estimated $2.24K sold.

Macquarie Group first reported a position in CUE in Q2 2020 and held it in 9 quarters. The position peaked at $117K in Q3 2021. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Macquarie Group reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 60 Cue Biopharma shares in Q3 2024, an estimated $2.24K.
  • Macquarie Group first reported a position in Cue Biopharma in Q2 2020 and held it in 9 quarters.
  • Macquarie Group's Cue Biopharma position peaked at $117K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.